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ABSTRACT
Human induced pluripotent stem cell (iPSC) models of epilepsy are becoming a revolutionary
platform for mechanistic studies and drug discovery. The skyrocketing pace of epilepsy gene dis-
covery is vastly outstripping the development of in vivo animal models. Currently, antiepileptic
drug prescribing to patients with specific genetic epilepsies is based on small-scale clinical trials
and empiricism; however, rapid production of patient-derived iPSC models will allow for preci-
sion therapy. We review iPSC-based studies that have already afforded novel discoveries in dis-
eases with epileptic phenotypes, as well as challenges to using iPSC-based neurological disease
models. We also discuss iPSC-derived cardiomyocyte studies of arrhythmia-inducing ion channe-
lopathies that exemplify novel drug discovery and use of multielectrode array technology that
can be translated to epilepsy research. Beyond initial studies of Rett, Timothy, Phelan-
McDermid, and Dravet syndromes, the stage is set for groundbreaking iPSC-based mechanistic
and therapeutic discoveries in genetic epilepsies with the potential to impact patient treatment
and quality of life. STEM CELLS 2016;34:27–33
SIGNIFICANCE STATEMENT
This review describes the use of patient-derived induced pluripotent stem cells to model genetic
epilepsies.We discuss the important studies performed to date, as well as challenges and potential
limitations of this approach. In addition, a strategy of drug screening with patient-derived neurons
to achieve precision therapy is described, along with future directions in the induced plurioptent
stem cell field for modeling epilepsies and other neurodevelopmental disorders.
INTRODUCTION
Modeling genetic epilepsies has long been
accomplished through the use of animal models
(mainly rodents) and heterologous expression
systems. The focus has largely been on genetically
modified mice over the past 15 years. Despite
many groundbreaking discoveries, these systems
present many challenges for fully recapitulating
human disease mechanisms and allowing the
possibility of mutation-specific drug discovery.
The development of human induced pluripotent
stem cell (iPSC) technology by Yamanaka and col-
leagues in 2007 opened the door to the rapid
production of patient-specific neuronal models of
disease and promises regenerative therapies in
the near future [1]. Disease modeling with iPSCs
circumvents the issues of murine genetic back-
ground and lack of neuronal environment for
mouse models and heterologous expression sys-
tems, respectively. While whole animal models
remain critical for studying acquired epilepsies
and examining network-based aspects of all epi-
lepsies, iPSCs are fast becoming a critical platform
for mechanistic studies at the cellular and molec-
ular levels, and for drug development (see [2] and
Fig. 1 therein).
To produce human iPSC lines, somatic cells—
typically dermal fibroblasts from a skin biopsy or
more recently blood-derived hematopoietic cells
[3]—are forced to express several transcription
factors necessary for reprogramming to the pluri-
potent state (e.g., combinations of OCT3/4,
SOX2, KLF4, C-MYC or L-MYC, LIN28, NANOG).
After 3–5 weeks in culture, iPSC colonies form at
a rate of typically 0.01%–0.1% of cells depending
upon the technique used to express the tran-
scription factors. These cells are an attractive sys-
tem for modeling genetic diseases because iPSCs
have an identical genome to the donor patient
and, using recent protocols that utilize episomal
vectors or Sendai virus, contain no exogenous
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Unlike primary cultures, iPSCs are naturally immortalized due to a
high expression of telomerase resulting in a theoretically infinite
supply of cells for study [6]. Numerous techniques for differenti-
ating iPSCs into particular neuronal subtypes and glia have been
published [7], allowing for modeling disease in many relevant cell
types, at a scale previously unattainable from patient tissues. The
rare and heterogeneous nature of genetic epilepsies lends itself
well to such a model since the production of transgenic animals
for all such mutations is logistically untenable.
Rapid progress in genome editing, particularly the utilization
of the TALEN (transcription activator-like effector nuclease) or,
more recently, the CRISPR/Cas9 (clustered regularly interspaced
short palindromic repeats/CIRSPR-associated protein 9 nuclease)
systems allows for rapid production of “virtual” patient iPSC lines
[8]. These lines are generated by editing a wild-type epileptic
gene in a control iPSC line to the mutated form found in an epi-
leptic patient. This procedure circumvents difficulties in obtaining
patient tissues and allows for comparisons with an isogenic con-
trol. Generating additional virtual patients on the same genetic
background also allows for controlled comparisons between spe-
cific patient mutations. The one downside to virtual patient gen-
eration is the loss of patient-specific genetic modifiers. An
alternative approach is to generate a patient-specific isogenic line
by correcting the patient mutation using CRISPR gene editing [9].
Isogenic controls are vital to definitively determine causality
between genotype and phenotype. Currently scarless gene edit-
ing of specific mutations (i.e., in the absence of other genome
modifications) in iPSCs, which does not allow for use of selectable
markers, is inefficient and can be painstakingly difficult for isolat-
ing a pure corrected line [10]. However, as gene-editing technol-
ogy becomes better adapted for iPSCs, isogenic controls will
almost certainly become a standard throughout the field.
GENETIC EPILEPSIES
Epilepsy is the fourth most common neurological disorder
behind Parkinson’s disease, Alzheimer’s disease, and stroke with
a prevalence of 7.1 cases per 1,000 [11]. Of these four diseases,
only epilepsy has a large portion of incidence in early life [12].
This early onset, along with increased mortality in epilepsy,
gives it the second highest neurological disease burden behind
stroke in terms of years of potential life lost [13]. With 30%–
40% of cases not adequately controlled with medication, epi-
lepsy poses a huge burden to individuals and families.
Only 25 years ago, the first genetic cause of epilepsy was
discovered [14]. Now, 500 loci are listed as potentially causa-
tive when mutated [15], and the pace of epilepsy gene dis-
covery continues to skyrocket. Although epilepsy can be
genetic or acquired, childhood epileptic encephalopathies
(CEEs) such as Dravet syndrome, infantile spasms, and
Lennox-Gastaut syndrome are increasingly linked to specific
mutations. These disorders also comprise some of the most
severe and pharmaco-resistant classes of epilepsy [16]. Recent
developments in whole exome and genome sequencing have
allowed for the identification of de novo mutations that con-
tribute to the development of CEEs [17–19]. Often after an
epilepsy gene is discovered, many more patients are identified
with mutations throughout the gene. In more than 80% of
Dravet syndrome cases, for example, mutations in the SCN1A
gene are causative, and more than 1,250 distinct mutations
(including missense, frameshift, truncation, deletion, and
splice sites) are currently identified in patients with SCN1A-
related epilepsies including Dravet syndrome, genetic epilepsy
with febrile seizures plus, intractable childhood epilepsy with
generalized tonic-clonic seizures, and infantile spasms [20,
21]. The impracticality of sufficient animal modeling of many
genetic epilepsies is underscored by the massive mutation
diversity. Unlike mouse models, the development of an iPSC
model can take a month with a distinctly lower cost while
preserving the exact genetics of the patient. Additionally, per-
haps 20% of CNS genes show distinct cortical expression pat-
tern differences between mouse and human, further
highlighting the need for human models [22]. Moreover, het-
erologous expression systems may fail to determine precise
disease mechanisms without the full complement of interact-
ing proteins, splicing patterns, and other factors unique to
neurons.
IPS DISEASE MODELS WITH EPILEPTIC PHENOTYPES
Since the advent of iPSC technology, CNS disorders have com-
prised a large portion of published disease models. This is not
surprising considering the limited access and growth potential
of primary patient-derived brain samples. For the purposes of
this review, we will focus on genetic epilepsies or genetic
brain diseases with epileptic symptoms in a subset of patients
(summarized in Table 1). Patient-derived iPSC models for
many of these diseases have demonstrated altered neuronal
morphology including soma size, neurite outgrowth, synapse
formation, and dendritic spine length. Additionally, altered
spontaneous activity and ion current density have been seen
in some of these disease models.
Rett syndrome is perhaps the epileptic disorder most stud-
ied via iPSCs. Rett syndrome is caused by mutations in the
methyl CpG binding protein 2 gene (MeCP2) on the X chromo-
some, and 50%–90% of Rett syndrome patients have seizures
[23]. Rett syndrome iPSC models from several groups show
decreases in neuronal soma size, neurite outgrowth, synapse
formation, and spontaneous activity compared to isogenic con-
trols [24, 25]. Marchetto et al. also demonstrated rescue of the
MeCP2 mutation associated phenotypes via insulin-like growth
factor-1 (IGF1) treatment [24]. It should be noted that wild-type
neurons had similar abnormal morphological phenotypes when
cocultured with iPSC-derived astrocytes from Rett syndrome
patients, underscoring the need to consider astrocytic contribu-
tions to epileptogenesis in addition to the neuronal contribu-
tion [26]. The Hanefeld variant of Rett syndrome is caused by
mutations in CDKL5 and typically presents with intractable seiz-
ures starting before 6 months of age. Neurons differentiated
from a CDKL5 mutant Rett syndrome patient iPSC line and pri-
mary neurons from a CDKL5 mutant mouse had reduced syn-
apse formation with increased dendritic spine length [27]. More
recent work tied together these two forms of Rett syndrome by
showing that the only expression change common to the
MeCP2 and CDKL5 variants in iPSCs was an upregulation in
GRID1, which encodes for the glutamate D1 receptor. This
protein acts as a synaptic adhesion molecule, and MeCP2 binds
to the promoter region [28].
The developmental disorder Phelan-McDermid syndrome (PMS)
is usually caused by loss of a long arm segment of chromosome 22
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and approximately 25% of patients have seizures [29]. The lost chro-
mosome segment contains the synaptic scaffolding gene, SHANK3.
One study cocultured control and patient iPSC-derived cortical neu-
rons with green (GFP) and red (mKate2) reporters to distinguish the
two lines [30]. This allowed the authors to perform electrophysiolog-
ical and cytoarchitectural analyses with reduced variability based on
culture conditions such as the culture-specific ratio of glutamatergic
and GABAergic neurons. PMS patient cells had reduced synapse for-
mation and spontaneous activity, which was rescued by SHANK3
overexpression or by addition of IGF1 [30].
Fragile X syndrome (FXS) is the most common genetic
cause of intellectual disability and presents with seizures in
10%–20% of cases [31]. Patient iPSC-derived neuronal models
of FXS have shown reductions in neurite length and synapse
formation as well as increased transient calcium current fre-
quency and amplitude [32]. These differences may be due to
a downregulation of RE1-silencing transcription (REST) factor
regulated genes responsible for axon guidance due to lower
microRNA-382 expression found in another iPSC study [33].
MODELING ION CHANNELOPATHIES
Epilepsies induced by channelopathies are ripe for both mech-
anistic and drug screening studies in iPSC-derived neurons
and astrocytes. While the functions of many epileptic genes
discussed in the previous section are still being worked out,
the basic functions of ion channels have been extensively
studied and defined. The effects of these mutations are also
cell autonomous while the synaptic and connectivity deficits
identified in Rett syndrome, FXS, and PMS require networks
to produce disease-related excitability phenotypes. Heteroge-
neity in network formation could, therefore, confound drug
screening for synaptic disorders. Additionally, the majority of
antiepileptic drugs currently approved by the FDA are known
to act on ion channels, particularly inhibition of voltage-gated
sodium channels as well as the GABA receptor chloride chan-
nel. Although drugs have been indicated or contraindicated
for particular types of epilepsies based on small clinical stud-
ies, the use of an in vitro drug-screening platform for patients
with rare channelopathies should—at the very least—give a
clearer rational for prescribing a particular drug to a particular
patient. To this end, we describe the currently reported iPSC-
based studies of putative epilepsy-causing channelopathies in
Timothy and Dravet syndromes.
Timothy syndrome is caused by mutations in the voltage-
gated calcium channel gene CACNA1C encoding the protein
CaV1.2. It leads to both cardiac (Long QT Syndrome [LQTS])
and neurological (autism and epilepsy) abnormalities. Several
studies from Ricardo Dolmetsch describe modeling this dis-
ease using iPSCs derived from patients with a G406R muta-
tion in CACNA1C. In cardiomyocytes, the mutation was found
to increase action potential durations due to impaired CaV1.2
channel inactivation. This was reversed with the calcium chan-
nel blocker, roscovitine [34]. In neurons differentiated from
the same patient iPSC lines, action potential width and sus-
tained calcium current were increased. These alterations were
blocked by the L-type calcium channel blocker, nimodipine
[35]. By showing rescue of disease-related electrophysiological
phenotypes, this group has identified a potential therapy for this
disease and proof-of-principle for the efficacy of drug develop-
ment using patient iPSC-derived neurons and cardiomyocytes.
Dravet syndrome is an infantile onset epileptic disorder
characterized by refractory epilepsy and cognitive dysfunction.
As mentioned earlier, approximately 80% of Dravet syndrome
cases are caused by mutations in the NaV1.1 voltage-gated
sodium channel encoding gene, SCN1A. Several groups have
modeled Dravet syndrome using patient-specific iPSCs with var-
ious reported phenotypes. Higurashi et al. showed impaired
action potential generation in primarily GABAergic cells from a
patient with a predicted truncation at residue 1,645 of the
NaV1.1 protein suggesting loss-of-function [36]. In contrast, Jiao
et al. showed significant increases in spontaneous activity and
sodium current density, particularly persistent sodium current,
in lines from two patients with missense mutations (F1415I
and Q1923R) using iPSC-derived neurons or glutamatergic neu-
rons directly converted from fibroblasts [37]. These reports
Table 1. Summary of epileptic disease induced pluripotent stem cell studies
Gene Disease
% of cases
with seizures Publication(s) Major findings
SCN1A Dravet syndrome 100% Liu et al. (2013),
Jiao et al. (2013),
Higurashi et al. (2013)
Altered sodium current density, spontane-
ous activity
CDKL5 Hanefeld variant Rett syndrome 100% Livide et al. (2014) Increased dendritic protrusions, decreased
synaptic formation
UBE3A Angelman syndrome 90% Chamberlain et al. (2010) Parental imprinting maintained during
reprogramming
MeCP2 Rett syndrome 50%–90% Marchetto et al. (2010),
Cheung et al. (2011),
Ananiev et al. (2011),
Kim et al. (2011),
Hotta et al. (2009)
Reduced soma size, neurite outgrowth,
VGLUT1 positive puncta density, and
spontaneous postsynaptic currents. IGF1
rescued some phenotypes
CYFIP2 15q11.2 microdeletion 66% Yoon et al. (2014) Altered neuroprogenitor organization and
polarity
SHANK3 Phelan-McDermid syndrome 25% Shcheglovitov et al. (2013) Defects in excitatory synapse formation
CACNA1C Timothy syndrome 20% Pasca et al. (2011) Increased action potential duration,
impaired voltage-gated calcium channel
inactivation, phenotypes blocked by L-
type calcium channel blockers
FMR1 Fragile X 10%–20% Urbach et al. (2010), Sheridan et al.
(2011), Liu et al. (2012)
Decreased neurite outgrowth
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would suggest loss-of-function mutations lead to decreased
GABAergic activity or increased sodium current and hyperexcit-
ability of glutamatergic cells. A third study demonstrated ele-
vated sodium current density and spontaneous activity in both
putative GABAergic and glutamatergic cell types with two
patient lines with loss-of-function mutations (IVS1413A>T and
truncation Y325X) [38]. This counterintuitive result of sodium
channel loss-of-function mutations leading to hyperexcitability
may be explained by compensation by the expression of other
voltage-gated sodium channels, such as NaV1.6.
While relatively few channelopathies of the CNS have
been modeled in iPSCs, many more studies have used iPSC-
derived cardiomyocytes to model channelopathies resulting in
cardiac dysfunction similar to the Timothy syndrome study
discussed earlier [34]. Using iPSC-derived cardiomyocytes from
a LQTS patient, a mutation in the KCNH2 potassium channel
gene was found to reduce rectifying potassium current
needed to repolarize cells leading to prolonged action poten-
tial duration [39]. These cells were then used at the single
and multicellular level to assay drugs known to alter LQTS.
This model faithfully recapitulated the expected drug effects
and allowed for characterization of novel therapeutics. Similar
studies have also been carried out in patients with SNC5A
and KCNQ1 mutations [40, 41].
CHALLENGES TO IPSC-BASED EPILEPSY MODELING
While patient-derived iPSCs are fast becoming an economical
and feasible model of human disease and pharmacology,
many challenges for their use in modeling genetic epilepsies
remain to be overcome. First, iPSC lines can have variable
expression profiles and differentiation potential. One study
demonstrated decreased efficiency of iPSCs, as compared to
human embryonic stem cells (ESCs), in their ability to differ-
entiate into PAX61 neural progenitors, an important first
step in differentiating many CNS neuronal subtypes [42]. This
variability is due, in part, to epigenetic differences from the
donor somatic cell retained from incomplete reprogramming
[43]. Gene expression profiling such as with the Pluritest are
now being used to validate individual iPSC lines by compar-
ing gene expression data to a large set of ESC lines [44].
These efforts should decrease some differentiation variability;
however, heterogeneity is a common theme in differentia-
tion of ESCs and iPSCs into neuronal subtypes [45]. No cul-
ture is a pure population unless flow cytometry techniques
are used. Unfortunately, few neuronal or astrocytic subtypes
have a distinguishing extracellular protein to allow for
antibody-dependent flow cytometry, and mature neurons
cannot tolerate such sorting. Most sorting procedures rely
on either pan-neuronal markers or promoter-driven fluores-
cent proteins.
A critical issue for epilepsy studies is that human iPSC-
derived neurons take dramatically more time for electrophysi-
ological properties and synaptic connections to mature in cul-
ture compared to mouse iPSCs [46]. This prolongation is
presumably due to developmental timing that matches in vivo
human development. Many compounds have been used to
accelerate the rate of maturation including gamma secretase
inhibitors (DAPT and compound E) to block notch signaling.
Neurotrophic factors including brain-derived neurotrophic fac-
tor, glial-derived neurotrophic factor, nerve growth factor, and
neurotrophin-3 all increase neuronal survival as well as matu-
ration. Neuronal maturation is also enhanced when iPSC-
derived neural progenitors are cocultured with either human
or rodent astrocytes, as measured by spontaneous firing, and
sodium and potassium current amplitude [47]. Techniques are
also available to differentiate astrocytes from patient iPSC lines
allowing for patient-specific astrocytic cultures. Such disease-
specific astrocytes will be particularly important in disorders
such as Rett syndrome that have an astrocytic component to
epileptogenesis, malformations of cortical development [48], or
possibly patients with mutations in astrocytic channels involved
in glutamate cycling, disorders of which may contribute to
both genetic and acquired epilepsies.
Despite the current advances in iPSC-derived neuronal
culture, many groups report depolarized resting potentials
and small percentages of neurons that undergo evoked firing
in patch-clamp recordings. These issues are not typical of pri-
mary neuronal cultures, demonstrating a challenge to fully
differentiating iPSC-derived neurons. In comparison to the
electrophysiological recordings of human fetal neurons, the
properties seen may merely recapitulate the properties of
neurons in utero [49]. However, recently, a cell culture
medium has been developed that appears to stimulate mat-
uration and support electrophysiological function of iPSC-
derived neurons, suggesting that this obstacle with the previ-
ously reported culture conditions will soon be overcome
[50].
THE FUTURE
The future of iPSC-based modeling of genetic epilepsies portends
high-throughput screening for new pharmaceuticals for rare dis-
eases leading to precision therapy. These studies are underway in
human iPSC-derived cardiomyocytes in patients with genetic
arrhythmias via multielectrode array (MEA) recordings. MEAs
allow for real-time spontaneous activity measurement from hun-
dreds of neurons simultaneously under normal culture condi-
tions. If the issues discussed in the previous section are
adequately overcome (i.e., cell type heterogeneity, neuronal mat-
uration), the effects of compound libraries on neuronal activity
can be assayed and compared between control and patient cells.
Finding patient-specific activity phenotypes would allow for the
identification of pharmaceuticals that specifically target the
patient disease mechanism with limited effects on normal neuro-
nal activity. The best example to date was performed in SOD1
mutant amyotrophic lateral sclerosis (ALS) patient iPSC-derived
neurons [51]. This study identified a hyperexcitable phenotype in
the patient cells using a MEA platform. Patch-clamp recordings
identified reduced potassium current density as the most likely
cause, and a potassium channel opener, retigabine, blocked the
hyperexcitability. In the same way, we anticipate that iPSC epi-
lepsy models will produce activity-dependent phenotypes on
MEAs that can subsequently be leveraged in drug-screening
assays (as depicted in Fig. 1). Before large screenings can be per-
formed, the sensitivity of the assay to detect changes in activity
must be determined. Neurotoxicological screening in rat primary
cortical cultures showed that a MEA identified 87% of known
positive compounds and 100% of negative compounds using
three to seven wells with 64 electrodes per well [52]. These data
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suggest that a small number of samples can determine a “hit” on
a large drug screen; however, similar studies must be performed
in human iPSC-derived neurons to determine their screening
potential compared to rodent primary neurons.
Uses for human iPSCs in modeling epilepsies go beyond
routine cell culture and MEA recordings. Recently a group has
reported the generation of cerebral organoids by three-
dimensional culture [53]. Remarkably, the cultures preserved
the dorsal forebrain-like progenitor zone and primitive cortical
laminar patterning, as well as regional marker (albeit not
structural) specification of the hippocampus and ventral fore-
brain. This model system will be important for genetic neuro-
developmental disorders that often incorporate both epilepsy
and cortical developmental abnormalities. Cerebral organoids
are amenable to calcium imaging [53] and acute in vitro slice
recordings to assess cortical excitability. Alternatively, patient
iPSC-derived neurons can also be transplanted in utero into
rodent models allowing for in vivo analysis of developmental
integration of neurons and their electrophysiological proper-
ties as has been previously performed [54, 55]. One must
keep in mind that animals injected with human cells should
not be bred to avoid potential germline transmission, and the
number of cells injected should be limited to avoid drastically
altering brain morphology and function.
CONCLUSIONS
iPSC technology provides an unprecedented ability to model
genetic disease. A growing number of epileptic disease models
using patient-derived neurons and astrocytes have already provided
novel insights into disease mechanisms. However, the vast number
of de novo epileptic gene discoveries being made in recent years
suggests that the field has only scratched the surface of iPSC-based
model potential in the genetic epilepsies. Despite the list of chal-
lenges and caveats to using iPSC models, this burgeoning field has
already demonstrated rapid solutions to early challenges and prom-
ises continued progress. We contend that the current state of iPSC
modeling will soon allow for drug discovery that will improve ther-
apy in patients with severe genetic epilepsies.
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Figure 1. Antiepileptic drug screening of genetic epilepsy patient induced pluripotent stem cell-derived neurons by multielectrode
array (MEA). Upper left: Depiction of a 96-well-plate MEA used on the Maestro platform (Axion Biosystems). Each well incorporates
eight recording electrodes with four ground electrodes (enlargement, upper middle). Upper right: Representative raster plots generated
from eight recording electrodes on the Maestro platform. Lower left: Drug-dependent activity (spike rate) heat map generated by divid-
ing the experimental MEA activity by a baseline read. Lower right: % of control activity is plotted for each drug, and “hits” in red are
defined by a predetermined significance threshold. These hits will then be validated by concentration response curves via MEA (sponta-
neous activity) and patch-clamp recordings (ionic currents).
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